Study identifier:7054IL/0044
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Randomised, double-blind, placebo controlled, parallel-group, multicentre Phase II study to assess dose response relationship of Nolvadex (oral tablet) in prophylactic treatment of gynaecomastia and breast pain associated with CASODEX 150 mg (oral tablet), and to assess the tumour control…..
Gynaecomastia
Phase 2
No
Casodex, Tamoxifen
Male
-
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: Casodex 150mg once daily |
Active Comparator: 2 | - |